| Primary |
| Lung Transplant |
18.2% |
| Systemic Candida |
15.2% |
| Fungal Peritonitis |
12.1% |
| Fungal Infection |
9.1% |
| Peritonitis |
9.1% |
| Antifungal Treatment |
6.1% |
| Candidiasis |
6.1% |
| Fungaemia |
6.1% |
| Abdominal Infection |
3.0% |
| Escherichia Infection |
3.0% |
| H1n1 Influenza |
3.0% |
| Lung Infection |
3.0% |
| Pneumonia Viral |
3.0% |
| Yeast Infection |
3.0% |
|
| Death |
9.5% |
| Aspartate Aminotransferase Increased |
4.8% |
| Candida Sepsis |
4.8% |
| Cardiac Failure |
4.8% |
| Cardiac Failure Acute |
4.8% |
| Deafness |
4.8% |
| Fungal Peritonitis |
4.8% |
| Fungal Test Positive |
4.8% |
| Haemolysis |
4.8% |
| Hepatic Enzyme Increased |
4.8% |
| Hyponatraemia |
4.8% |
| Inappropriate Antidiuretic Hormone Secretion |
4.8% |
| Mediastinitis |
4.8% |
| Multi-organ Failure |
4.8% |
| Off Label Use |
4.8% |
| Renal Failure |
4.8% |
| Tachycardia |
4.8% |
| Thrombotic Thrombocytopenic Purpura |
4.8% |
| Toxic Epidermal Necrolysis |
4.8% |
| Vomiting |
4.8% |
|
| Secondary |
| Extranodal Nk/t-cell Lymphoma, Nasal Type |
16.4% |
| Bronchopulmonary Aspergillosis |
13.4% |
| Pneumonia |
10.4% |
| Prophylaxis |
8.3% |
| Product Used For Unknown Indication |
6.8% |
| Sepsis |
5.6% |
| Skin Candida |
4.8% |
| Rheumatoid Arthritis |
4.6% |
| Antifungal Prophylaxis |
4.5% |
| Obliterative Bronchiolitis |
4.0% |
| Fungal Infection |
3.6% |
| Febrile Neutropenia |
2.6% |
| Diffuse Large B-cell Lymphoma Stage Iv |
2.0% |
| Pneumonia Klebsiella |
2.0% |
| Pseudomonas Infection |
2.0% |
| Pulmonary Necrosis |
2.0% |
| Acute Lymphocytic Leukaemia |
1.8% |
| Aspergillosis |
1.8% |
| Hypertension |
1.8% |
| Bronchitis |
1.7% |
|
| Drug Ineffective |
16.0% |
| Bronchopulmonary Aspergillosis |
12.3% |
| Zygomycosis |
8.6% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
6.2% |
| Subacute Hepatic Failure |
6.2% |
| Trichosporon Infection |
4.9% |
| Candida Infection |
3.7% |
| Drug Resistance |
3.7% |
| Encephalitis Fungal |
3.7% |
| Hepatic Function Abnormal |
3.7% |
| Pneumonia |
3.7% |
| Pyrexia |
3.7% |
| Shock |
3.7% |
| White Blood Cell Count Decreased |
3.7% |
| White Blood Cell Count Increased |
3.7% |
| Cryptosporidiosis Infection |
2.5% |
| Drug Ineffective For Unapproved Indication |
2.5% |
| Fungal Sepsis |
2.5% |
| Multi-organ Failure |
2.5% |
| Pancreatitis |
2.5% |
|
| Concomitant |
| Product Used For Unknown Indication |
33.0% |
| Prophylaxis |
8.8% |
| Nausea |
5.6% |
| Drug Use For Unknown Indication |
5.3% |
| Acute Myeloid Leukaemia |
4.9% |
| Hypertension |
4.4% |
| Pain |
4.3% |
| Infection Prophylaxis |
4.2% |
| Bone Marrow Conditioning Regimen |
3.7% |
| Sedation |
3.2% |
| Acute Lymphocytic Leukaemia |
3.1% |
| Prophylaxis Against Graft Versus Host Disease |
3.0% |
| Constipation |
2.7% |
| Infection |
2.4% |
| Antifungal Prophylaxis |
2.4% |
| Prophylaxis Of Nausea And Vomiting |
2.2% |
| Graft Versus Host Disease |
1.9% |
| Premedication |
1.7% |
| Anti-infective Therapy |
1.6% |
| Pyrexia |
1.6% |
|
| Sepsis |
10.2% |
| Respiratory Failure |
8.5% |
| Drug Ineffective |
6.8% |
| Pneumonia |
6.8% |
| Thrombocytopenia |
6.8% |
| Renal Failure |
6.3% |
| Pyrexia |
5.7% |
| Vomiting |
5.7% |
| White Blood Cell Count Decreased |
5.7% |
| Death |
5.1% |
| Nephropathy Toxic |
4.0% |
| Posterior Reversible Encephalopathy Syndrome |
4.0% |
| Septic Shock |
4.0% |
| Hyperbilirubinaemia |
3.4% |
| Alanine Aminotransferase Increased |
2.8% |
| Bk Virus Infection |
2.8% |
| Failure To Thrive |
2.8% |
| Platelet Count Decreased |
2.8% |
| Pleural Effusion |
2.8% |
| Pneumocystis Jiroveci Pneumonia |
2.8% |
|
